Strategic Initiative
Slingshot members are tracking this corporate initiative:
Amygdala Neurosciences Licenses Substance Abuse Candidate GS-6637 from Gilead (GILD) for Undisclosed Sum
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| GILD |
|
|
Amygdala Neurosciences |
|
|
|
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date: Feb 16, 2017 Projected Implementation: Q1, 2017 Relevance Tracked Until: Q1, 2018
Related Projects
-
Don’t see a project related to the strategic initiative you care about?
Related Keywords
Substance Abuse, Gs-6637
